News AstraZeneca cuts the ribbon on its $1bn R&D lab in Cambridge After years of delays and rising costs, AstraZeneca has formally unveiled its $1 billion R&D facility in
Events Partner Content 3rd Lab Asset & Facility Management in Pharma Summit Maximize Your Asset Value & Optimize Your Facility
Oncology Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.
